Halixol, tablets 30 mg 20 pcs

An expectorant (mucolytic) drug. Ambroxol is the active metabolite of bromhexine, belongs to the benzylamine group of mucolytic substances.

Thickens sputum by increasing the production and activity of hydrolytic enzymes which break the bonds between mucopolysaccharides of sputum.

It improves rheological properties of sputum by reducing its viscosity and adhesive properties due to stimulation of serous cells of the bronchial mucous membrane glands and normalization of the ratio of the mucous and serous components of sputum.

increases mucociliary transport by increasing the motor activity of the atrial epithelium. It does not cause excessive secretion and reduces spastic bronchial hyperresponsiveness.

Promotes the production of surfactant.

The effect occurs within 30 minutes after taking the drug.

Indications

Inflammatory diseases of the ENT organs (sinusitis, otitis), which require thinning the mucus. Acute and chronic diseases of the respiratory system, accompanied by the formation of viscous sputum: bronchitis, bronchial asthma, COPD, pneumonia, bronchiectasis.

Pharmacological effect

Expectorant (mucolytic) drug. Ambroxol is an active metabolite of bromhexine and belongs to the benzylamine group of mucolytic substances.

It thins sputum by enhancing the production and increasing the activity of hydrolytic enzymes that break down the bonds between sputum mucopolysaccharides.

Improves the rheological properties of sputum, reducing its viscosity and adhesive properties, by stimulating the serous cells of the glands of the bronchial mucosa and normalizing the ratio of the mucous and serous components of sputum.

Increases mucociliary transport, increasing the motor activity of the ciliated epithelium. Does not cause excessive secretion formation, reduces spastic hyperreactivity of the bronchi.

Promotes the production of surfactant.

The effect develops 30 minutes after taking the drug.

Special instructions

It should not be prescribed simultaneously with antitussive drugs due to difficulty in sputum production.

The use of the drug in patients with impaired bronchial motor function or excessive production of low-viscosity sputum requires caution due to the danger of stagnation of bronchial secretions.

The syrup contains non-specific sweeteners, sorbitol, sodium cyclamate, so patients with diabetes can use this drug, however, the sorbitol content (1.2 g per 5 ml) should be taken into account by patients with diabetes.

The drug does not contain alcohol.

Active ingredient

Ambroxol

Composition

1 tablet contains:

Active ingredient:

ambroxol hydrochloride 30 mg;

Excipients:

lactose monohydrate – 84 mg;

MCC – 30 mg;

povidone K30 – 5 mg;

sodium carboxymethyl starch (type A) – 10 mg;

magnesium stearate – 1 mg.

Pregnancy

The drug is contraindicated for use in the first trimester of pregnancy.

Ambroxol is excreted in breast milk, so if it is necessary to use the drug during lactation, the issue of stopping breastfeeding should be decided.

Contraindications

ulcerative lesions of the gastrointestinal tract;
I trimester of pregnancy;
lactation period (breastfeeding);
hypersensitivity to ambroxol or bromhexine;
the drug in tablet form is not intended for use in children under 5 years of age.

The drug should be used with caution in severe renal failure.

Side Effects

From the side of the central nervous system: rarely – weakness, headache.

From the digestive system: rarely – diarrhea, constipation, dry mouth, gastralgia, nausea, vomiting.

From the respiratory system: rarely – dry airways, rhinorrhea.

Allergic reactions: rarely – exanthema, urticaria; extremely rarely – acute anaphylactic reactions, the causal relationship of which with taking ambroxol has not been established.

Other: dysuria.

Interaction

Antitussive drugs (including codeine) may make it difficult to produce sputum thinned by ambroxol.

Halixol® promotes the penetration of certain antibiotics into the bronchial secretions (including amoxicillin, cefuroxime, erythromycin, doxycycline).

Overdose

Symptoms: nausea, vomiting, diarrhea, dyspepsia.

Treatment: induce vomiting, then prescribe drinks (milk or tea), and intake of fat-containing foods. Gastric lavage is recommended within 1-2 hours after taking the drug. The function of the cardiovascular system should be constantly monitored.

Storage conditions

In a place protected from light, at a temperature not exceeding 30 °C

Shelf life

5 years

Manufacturer

EGIS, Hungary